Codexis Prices at Bottom of Range

U.S. biotech company Codexis priced shares in its initial public offering at the bottom of the expected range on Wednesday in its second attempt to list its shares for public trade.

The Redwood City, Calif.-based company sold 6 million shares for $13 each, raising about $78 million. It had planned to sell shares for between $13 and $15 each. Codexis sells enzymes and microbes modified to make industrial processes cleaner and faster. It also sells its "biocatalysts" to pharmaceutical companies including Merck & Co, Pfizer and Dr Reddy's Laboratories. It is also working with Royal Dutch Shell on cellulosic biofuels -- biofuels that are made from plants like wheat straw.

Total revenue rose more than 64% to $82.9 million in 2009. The company cut its losses 55% to $20.3 million in the same period. Codexis said in its prospectus that it does not expect to be profitable until at least 2011. Major shareholders in Codexis include funds associated with Maxygen, Shell, the Singaporean government, CMEA Ventures, FirstMark Capital and Chevron Corp. Underwriters were led by Credit Suisse. The shares are expected to begin trading on the Nasdaq on Thursday under the symbol "CDXS."

Company

Codexis

200 Penobscot Drive
Redwood City

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read